Skip to main content
Skip to content
1 duplicate copy in the archive
Case File
d-26789House Oversight

Aetna analyst note projects AET/HUM merger approval and financial outlook

Other

The passage is a routine investment thesis with no allegations, financial flows, or misconduct involving high‑profile officials. It merely forecasts a potential merger approval and stock performance, Predicts AET/HUM deal approval by courts in January 2017 Forecasts 2018 EPS around $11.50, above consensus Notes potential share repurchase of ~10% if deal falls through

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #014624
Pages
1
Persons
11
Integrity
No Hash Available
Loading document viewer...

Ask AI About This Document

0Share
PostReddit
Review This Document

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.